Dr. Chris Chen is the Chief Executive Officer of WuXi Biologics, a Hong Kong–listed and global leading biologics contract research, development, and manufacturing organization (CRDMO). Under Dr. Chen’s leadership, WuXi Biologics has built a world-class integrated biologics discovery, development, and manufacturing platform, enabling over 450 global partners ranging from small firms to top 20 global pharmaceutical companies. Dr. Chen’s extensive experience in monoclonal antibodies (mAb), therapeutic proteins, and vaccines has been recognized by industry leaders. Dr. Chen serves on the International Board of Directors for the International Society for Pharmaceutical Engineering (ISPE) and is the first board member from Asia.